SG11202002169TA - Composition and method for treating autism - Google Patents
Composition and method for treating autismInfo
- Publication number
- SG11202002169TA SG11202002169TA SG11202002169TA SG11202002169TA SG11202002169TA SG 11202002169T A SG11202002169T A SG 11202002169TA SG 11202002169T A SG11202002169T A SG 11202002169TA SG 11202002169T A SG11202002169T A SG 11202002169TA SG 11202002169T A SG11202002169T A SG 11202002169TA
- Authority
- SG
- Singapore
- Prior art keywords
- composition
- treating autism
- autism
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/348—Cannabaceae
- A61K36/3482—Cannabis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2017903766A AU2017903766A0 (en) | 2017-09-15 | Composition and method for treating autism | |
| AU2018900276 | 2018-01-18 | ||
| PCT/AU2018/051010 WO2019051560A1 (en) | 2017-09-15 | 2018-09-14 | Composition and method for treating autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002169TA true SG11202002169TA (en) | 2020-04-29 |
Family
ID=63831830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002169TA SG11202002169TA (en) | 2017-09-15 | 2018-09-14 | Composition and method for treating autism |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20200276155A1 (en) |
| EP (1) | EP3681525A4 (en) |
| JP (1) | JP2021500312A (en) |
| CN (1) | CN111263638A (en) |
| AU (2) | AU2018101357B4 (en) |
| CA (1) | CA3075122A1 (en) |
| CL (1) | CL2020000632A1 (en) |
| IL (1) | IL273278A (en) |
| SG (1) | SG11202002169TA (en) |
| WO (1) | WO2019051560A1 (en) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201900665VA (en) | 2016-08-03 | 2019-02-27 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| BR112019026877A2 (en) | 2017-06-19 | 2020-06-30 | Zelda Therapeutics Operations Pty Ltd | sleep disorder compositions and treatments |
| CA3300266A1 (en) | 2017-09-28 | 2026-03-02 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| US12582664B2 (en) | 2017-09-28 | 2026-03-24 | Harmony Biosciences Management, Inc. | Treatment of fragile x syndrome with cannabidiol |
| CA3089994A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
| EP3807385A1 (en) * | 2018-06-14 | 2021-04-21 | Biosoma B.V. | Process for the extraction of oil-soluble components from plant material |
| AU2019285379A1 (en) * | 2018-06-15 | 2021-02-04 | CannPal Animal Therapeutics Limited | Cannabinoid composition and methods of treatment using the same |
| WO2020077153A1 (en) | 2018-10-10 | 2020-04-16 | Canopy Holdings, LLC | Synthesis of cannabigerol |
| CA3122735A1 (en) | 2018-12-14 | 2020-06-18 | Zynerba Pharmaceuticals, Inc. | Treatment of 22q11.2 deletion syndrome with cannabidiol |
| EP3934641A4 (en) * | 2019-03-07 | 2022-12-21 | Ilera Therapeutics LLC | FORMULATIONS FOR THE TREATMENT OF SYMPTOMS OF GROUPS ASSOCIATED WITH AUTISM SPECTRUM DISORDER |
| IT201900014901A1 (en) * | 2019-08-21 | 2021-02-21 | Energicamente S R L | METHOD FOR PREPARING CANNABIS OIL |
| WO2021077108A1 (en) * | 2019-10-18 | 2021-04-22 | The Children's Hospital Of Philadelphia | Method of treating autism |
| US20210369643A1 (en) * | 2020-05-26 | 2021-12-02 | Zynerba Pharmaceuticals, Inc. | Treatment of fragile x syndrome and autism spectrum disorder with cannabidiol |
| KR20230113622A (en) * | 2020-12-03 | 2023-07-31 | 지네르바 파마슈티컬스, 인코포레이티드 | Cannabidiol for the treatment of refractory seizures |
| CN116782891A (en) * | 2020-12-03 | 2023-09-19 | Zyne制药公司 | Cannabidiol for the treatment of refractory epileptic seizures |
| PL4124336T3 (en) | 2021-07-30 | 2024-02-26 | Cannamedical Pharma Gmbh | Transmucosal patch comprising a cannabinoid and/or an opioid |
| AU2021107253A4 (en) * | 2021-08-24 | 2021-12-09 | Cymra Life Sciences Limited | A composition and uses thereof |
| CN118119397A (en) * | 2021-10-11 | 2024-05-31 | 神经科技国际有限公司 | Compositions and methods for treating neurological disorders |
| AU2022367003A1 (en) * | 2021-10-11 | 2024-03-28 | Neurotech International Ltd | Compositions and methods for treating neurological disorders with combination products |
| US20250262261A1 (en) * | 2021-10-11 | 2025-08-21 | Neurotech International Ltd | Compositions and methods for treating neurological disorders |
| WO2023140834A1 (en) * | 2022-01-19 | 2023-07-27 | Delmarva Hemp Llc | Method for solvent-free extraction and concentration of full spectrum of cannabinoids in a carrier oil |
| WO2024160792A1 (en) | 2023-01-30 | 2024-08-08 | Cannamedical Pharma Gmbh | Improved transmucosal patch comprising a cannabinoid and/or an opioid |
| AU2024324600A1 (en) * | 2023-08-11 | 2026-02-19 | Defloria Llc | Composition of cannabinoid extract of cw1as1 for the treatment of autism and associated symptoms |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10051427C1 (en) * | 2000-10-17 | 2002-06-13 | Adam Mueller | Process for the production of an extract containing tetrahydrocannabinol and cannabidiol from cannabis plant material and cannabis extracts |
| CH695661A5 (en) * | 2001-03-06 | 2006-07-31 | Forsch Hiscia Ver Fuer Krebsfo | Pharmaceutical composition. |
| ATE533472T1 (en) * | 2002-08-14 | 2011-12-15 | Gw Pharma Ltd | LIQUID CANNABINOID FORMULATIONS FOR ADMINISTRATION TO THE MUCOUS MEASURES |
| GB2439393B (en) * | 2006-06-23 | 2011-05-11 | Gw Pharma Ltd | Cannabinoids for use in the treatment of neuropathic pain |
| BR122021018502B1 (en) * | 2014-10-21 | 2022-05-03 | United Cannabis Corp | Liquid cannabinoid formulation |
| CA2986268C (en) * | 2015-05-28 | 2024-01-02 | Insys Development Company, Inc. | Stable cannabinoid formulations |
| WO2017151980A1 (en) * | 2016-03-03 | 2017-09-08 | Segreti Louis M | Cannabis-based bioactive formulations and methods for use thereof |
| WO2018023166A1 (en) * | 2016-08-03 | 2018-02-08 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| WO2018089863A1 (en) * | 2016-11-11 | 2018-05-17 | Bennes, Inc. | Formulations for efficient delivery of cannabinoids |
-
2018
- 2018-09-14 AU AU2018101357A patent/AU2018101357B4/en not_active Ceased
- 2018-09-14 JP JP2020515668A patent/JP2021500312A/en active Pending
- 2018-09-14 CN CN201880068202.6A patent/CN111263638A/en active Pending
- 2018-09-14 WO PCT/AU2018/051010 patent/WO2019051560A1/en not_active Ceased
- 2018-09-14 CA CA3075122A patent/CA3075122A1/en active Pending
- 2018-09-14 SG SG11202002169TA patent/SG11202002169TA/en unknown
- 2018-09-14 EP EP18856402.5A patent/EP3681525A4/en active Pending
- 2018-09-14 AU AU2018333282A patent/AU2018333282A1/en not_active Abandoned
- 2018-09-14 US US16/646,055 patent/US20200276155A1/en not_active Abandoned
-
2020
- 2020-03-11 CL CL2020000632A patent/CL2020000632A1/en unknown
- 2020-03-12 IL IL273278A patent/IL273278A/en unknown
-
2023
- 2023-05-25 US US18/323,860 patent/US20230364052A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018101357A4 (en) | 2018-10-18 |
| WO2019051560A1 (en) | 2019-03-21 |
| EP3681525A4 (en) | 2020-09-02 |
| JP2021500312A (en) | 2021-01-07 |
| IL273278A (en) | 2020-04-30 |
| AU2018333282A1 (en) | 2020-03-19 |
| CA3075122A1 (en) | 2019-03-21 |
| EP3681525A1 (en) | 2020-07-22 |
| CL2020000632A1 (en) | 2020-08-21 |
| CN111263638A (en) | 2020-06-09 |
| AU2018101357B4 (en) | 2022-03-17 |
| US20200276155A1 (en) | 2020-09-03 |
| US20230364052A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273278A (en) | Composition and method for treating autism | |
| ZA201800271B (en) | Treatment installation and method for treating workpieces | |
| ZA201800272B (en) | Treatment installation and method for treating workpieces | |
| IL251215A0 (en) | Cannabinoid composition and method for treating pain | |
| IL255463A (en) | Methods and kits for treating depression | |
| PT3490582T (en) | Methods and compositions for treating myelofibrosis | |
| SG11202003790PA (en) | Composition and method | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| IL254963A0 (en) | Compositions and methods for treating autism | |
| GB201520255D0 (en) | Composition and method | |
| SG10201706291TA (en) | Composition And Method For Treating Skin Conditions | |
| IL291266A (en) | Compositions and methods for treating infections | |
| ZA201907283B (en) | Compositions, devices and methods for treating autism | |
| IL271923A (en) | Methods and compositions for treating addictions | |
| GB201421385D0 (en) | Composition and method for treating nematodes | |
| ZA201904328B (en) | Composition, application thereof and treatment method | |
| GB201700116D0 (en) | Method and composition | |
| ZA201904187B (en) | Method and composition | |
| GB201509420D0 (en) | Composition and method | |
| EP3823593A4 (en) | Compositions and methods for treating autism | |
| IL260331A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
| IL261360A (en) | Composition and method for treating amyotrophic lateral sclerosis | |
| GB201513492D0 (en) | Method and composition | |
| ZA201904626B (en) | Cancer treatment method and composition | |
| PL3650431T3 (en) | Composition containing c8f17br and method for producing c8f17br |